Findings
The traditional process of evaluating biomarkers within the context of a single drug development program is inefficient and creates uncertainty for sponsors. This case-by-case approach leads to redundant efforts, slows down the development of novel therapies, and hinders the broad adoption of promising scientific tools. There is a clear need for a centralized, collaborative pathway to formally validate biomarkers, which can de-risk drug development, encourage innovation, and make the process more predictable and cost-effective for all stakeholders.

Recommendations
Drug developers, academic researchers, and other stakeholders should proactively engage with the FDA through the formal Biomarker Qualification Program to validate biomarkers for specific contexts of use. It is recommended to form public-private partnerships and other collaborations to pool resources and data, which strengthens the evidence package for a biomarker's utility. Developers should use the qualification process to establish a biomarker's value early, making it a publicly available and reliable tool that can accelerate the development of multiple drug products.

Regulatory Considerations
The Biomarker Qualification Program provides a distinct regulatory pathway for establishing a biomarker's validity for a specific Context of Use (COU), separate from an individual Investigational New Drug (IND) or New Drug Application (NDA). The process involves a three-stage submission and review cycle: the Letter of Intent, the Qualification Plan, and the Full Qualification Package. Once qualified, a biomarker is publicly listed and can be incorporated into multiple drug development programs without the need for sponsors to re-submit and re-justify the validation data for that specific COU, streamlining subsequent regulatory reviews.

Findings
MCID represents the smallest change that someone living with Alzheimer's disease would identify as important, but faces several universal application challenges. Alzheimer's disease progresses differently for each individual, complicating the establishment of universal standards that account for individual-level issues. The disease is gradual and evolving, with what is perceived as clinically meaningful varying significantly at early and late disease stages. People living with Alzheimer's disease and caregivers may have differing perspectives on treatment benefits, making it challenging to establish appropriate MCID. Current Alzheimer's trials rely on various tests to evaluate cognitive and functional impairments, but these tests often lack sensitivity to early-stage changes and are affected by variability in rater rankings. Digital biomarkers offer promising approaches for detecting real-time, objective clinical differences and improving patient outcomes through continuous monitoring, individualized assessments, and artificial intelligence learning for complex analytical predictions.

Recommendations
Digital biomarkers and advanced health technologies should be leveraged to enable continuous monitoring and individualized assessments that can better capture meaningful change in Alzheimer's disease. The primary focus must remain on outcomes that truly matter to people living with Alzheimer's disease and their caregivers, ensuring that the principle of clinical meaningfulness is not lost as new technologies are introduced.

Regulatory Considerations
Important considerations around standardization, accuracy, and integration into current clinical frameworks must be addressed as digital biomarkers are adopted. As new technologies are introduced alongside evolving regulatory frameworks, maintaining focus on clinically meaningful outcomes for patients and caregivers is essential.

Findings
There is a need for rapid development of solutions for monitoring Long COVID symptoms due to their variability and lack of treatment options.
Barriers include patient acceptability and the healthcare system's readiness for new technologies like vocal biomarkers.
The health status of patients, particularly those with severe symptoms, may limit their ability to participate in regular voice recordings, affecting adherence.

Recommendations
Involve end users in the co-design of digital health solutions to ensure they meet needs and expectations.
Develop telemonitoring solutions that allow for accurate follow-up and complement on-site evaluations.
Implement feedback loops to improve both the solution and the algorithm through lessons learned in population studies.
Ensure that voice data collection is diverse enough to represent the target population and decrease systemic biases.
Obtain explicit consent prior to voice data collection to comply with data protection regulations.

Regulatory Considerations
Voice data is considered identifying and sensitive, requiring compliance with various data protection laws.
Explicit consent is necessary for voice data collection to minimize future risks.
Validation through clinical trials is required to prove clinical benefit, effectiveness, and security.
CE marking or FDA certification will be mandatory to bring the solution to market.
Requests for reimbursement can be made after proving the clinical and economic interest of the digital system.

Findings
DMOs offer a novel method to monitor mobility performance in real-world conditions across multiple diseases, but no current gold standard exists for direct comparison.
A 24-month observational clinical study with disease-specific cohorts is considered a valid exploratory step for validating DMOs.
Disease-specific endpoints (e.g., EDSS for MS, FEV1 for COPD) are supported as anchors for evaluating DMOs’ predictive capacity and construct validity.
The Later-Life Function & Disability Instrument (LLFDI) requires additional validation for use as a disease-independent biomarker, especially in younger populations.
Validation of DMOs as surrogate endpoints is contingent upon demonstrating robust correlations with established clinical outcomes in each disease.

Recommendations
Continue using disease-specific endpoints (e.g., EDSS for MS, FEV1 for COPD) to validate DMOs within individual diseases.
Validate the LLFDI tool across diverse age groups and diseases to establish its utility as a disease-independent biomarker.
Explore combining multiple DMOs to enhance predictive capacity where applicable.
Focus on disease-specific biomarkers until sufficient evidence supports the use of DMOs as disease-independent endpoints.
Conduct randomized clinical trials as a follow-up to the observational study to evaluate DMOs’ responsiveness to therapeutic interventions.

Regulatory Considerations
Established endpoints must be used to validate DMOs for consideration as secondary endpoints in regulatory submissions.
Disease-specific validation should be prioritized over disease-independent validation until robust evidence supports the latter.
Provide standardized and regionally consistent criteria for endpoints such as care home admission (PFF) or fall frequency (PD).
Correlate DMOs with widely accepted clinical measures (e.g., FEV1 in COPD) to strengthen regulatory positioning.
Incorporate randomization in future studies to further validate DMOs as surrogate endpoints predictive of clinical outcomes.

Findings
Early and ongoing engagement with regulatory bodies is essential to align endpoint development with regulatory expectations.
There are distinct pathways for drugs and medical devices, with specific meeting types (e.g., Type B and Type C meetings) available for each.
Qualification programs help establish the utility and validity of digitally-derived endpoints across different drugs, devices, or diseases.
Regulatory agencies provide detailed feedback on analytical and clinical validation, ensuring endpoints meet clinical relevance and reliability standards.
The document emphasizes the importance of understanding and navigating distinct regulatory frameworks (e.g., IND/NDA for drugs and IDE/510(k) for devices).

Recommendations
Engage with regulatory bodies, such as the FDA and EMA, early in the development process to obtain critical input.
Utilize structured programs, like the Drug Development Tool (DDT) and Medical Device Development Tools (MDDT) qualification pathways, to validate endpoints.
Schedule appropriate regulatory meetings, including Type B and Type C meetings for drugs or Q-Submission and Agreement Meetings for devices.
Consider utilizing general advisory sessions (e.g., Critical Path Innovation Meetings or Innovation Task Force Briefings) to enhance endpoint development strategies.
Document and align endpoint development with regulatory frameworks, ensuring compliance with safety, efficacy, and performance standards.

Regulatory Considerations
Use FDA’s IND/NDA and IDE/510(k) pathways for endpoint validation, tailoring engagement to the specific type of medical product.
Schedule Type B and Type C meetings for focused discussions on endpoint development, including context of use and validation.
Engage with EMA through pre-submission meetings for scientific advice, ensuring endpoints meet requirements for clinical relevance and robustness.
Leverage qualification advice meetings with EMA for methodologies applicable across multiple products or diseases.
Seek assistance from regulatory initiatives, such as the FDA’s Digital Health Center of Excellence or EMA’s Qualification Advice Programs, for specialized guidance.

Findings
A universally applicable evidentiary standard for biomarker qualification is not feasible; the necessary level of evidence depends entirely on the specific Context of Use (COU). The framework emphasizes that the strength of evidence is evaluated based on the potential risk and benefit associated with the biomarker's intended application in drug development. The relationship between a biomarker and clinical outcomes must be robustly demonstrated, but there are no fixed quantitative criteria for this association. The overall confidence in a biomarker is derived from a combination of analytical validation, clinical validation, and the strength of the biological rationale.

Recommendations
Sponsors should clearly define the specific COU for the biomarker early in the development process, as this will dictate the required evidentiary support. It is recommended that sponsors engage with the FDA throughout the biomarker development and validation process to ensure alignment on the evidentiary requirements. Submissions for biomarker qualification should include a comprehensive package of evidence detailing the analytical validation (how well the test measures the biomarker) and the clinical validation (how well the biomarker relates to a clinical endpoint). Sponsors should provide a strong biological rationale for the biomarker's role in the disease process and its relevance to the proposed COU.

Regulatory Considerations
The FDA's evidentiary framework is designed to be a flexible, risk-based approach to biomarker qualification. The qualification is specific to the COU for which it was evaluated and does not imply acceptance for other uses. The framework is intended to support the use of biomarkers as Drug Development Tools (DDTs), which can include uses for patient selection, as surrogate endpoints, or to demonstrate a drug's mechanism of action. The level of regulatory scrutiny is proportional to the impact the biomarker will have on drug development and clinical decision-making. Qualified biomarkers can help to de-risk and streamline the drug development process.